Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130021/S174

Evolut PRO+ System, Evolut FX System, Evolut FX+ System

Medtronic, Inc. · Decision date Aug 27, 2025

FDA DECISIONP130021/S174

What did the FDA approve?

FDA records P130021/S174 as a supplement to PMA P130021, with the supplement type “Panel Track”. The recorded decision is approval, dated Aug 27, 2025.

FDA approval order statement

Approval for the Evolut PRO+ System, Evolut FX System, Evolut FX+ System for expanding the indications to include the treatment of patients with a failed trascatheter aortic valve who are at high or greater risk of mortality from open surgical therapy. This device is indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical or transcatheter bioprosthetic aortic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality >8% at 30 days, based on the STS risk score and other clinical co-morbidities unmeasured by the STS risk calculator).
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Cardiovascular
Decision date
Aug 27, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P130021/S174
Regulatory pathway
PMA supplement
Product code
NPT
Decision code
APPR
Decision date
Aug 27, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Aortic valve, prosthesis, percutaneously delivered.

Product code
NPT
FDA device class
3

For the original device and its historical approval scope, see PMA P130021. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P130021 · Original PMA

    MEDTRONIC COREVALVE SYSTEM

  2. P130021/S174 received

    Application receipt date recorded by FDA.

  3. P130021/S177 · Related supplement

    Medtronic CoreValve Evolut PRO Transcatheter Aortic Valve; Medtronic Evolut PRO+ Transcatheter Aortic Valve; Medtroni

  4. P130021/S174 · FDA decision

    Panel Track

  5. P130021/S178 · Related supplement

    Medtronic Evolut PRO+ Delivery Catheter System

  6. P130021/S180 · Related supplement

    Medtronic CoreValve Evolut PRO Transcatheter Aortic Valve (EVOLUTPRO-23-US, EVOLUTPRO-26-US, EVOLUTPRO-29-US); Medtron

  7. P130021/S183 · Related supplement

    Medtronic CoreValve Evolut PRO Transcatheter Aortic Valve; Medtronic Evolut PRO+ Transcatheter Aortic Valve; Medtroni

  8. P130021/S181 · Related supplement

    EnVeo PRO Delivery Catheter System (ENVPRO-16-US), Evolut PRO+ Delivery Catheter System (D-EVPROP2329US, D-EVPROP34US),

  9. P130021/S179 · Related supplement

    Evolut PRO, PRO+, FX, FX+

  10. P130021/S182 · Related supplement

    CoreValve EnVeo Pro Delivery Catheter System; Evolut PRO+ Delivery Catheter System; Evolut FX Delivery Catheter System

  11. P130021/S184 · Related supplement

    Medtronic CoreValve EnVeo PRO Delivery Catheter System; Medtronic Evolut PRO+ Delivery Catheter System; Medtronic Evolut

  12. P130021/S186 · Related supplement

    Medtronic CoreValve Evolut PRO Transcatheter Aortic Valve

  13. P130021/S185 · Related supplement

    Medtronic Evolut PRO+ Transcatheter Aortic Valve Replacement System; Medtronic Evolut FX Transcatheter Aortic Valve Repl

  14. P130021/S187 · Related supplement

    Medtronic Evolut FX Delivery Catheter System; EvolutTranscatheter Aortic Valve System

  15. P130021/S188 · Related supplement

    Evolut FX Delivery Catheter System of the Evolut FX Transcatheter Aortic Valve System; Evolut FX+ Transcatheter Aorti

Timeline entries are records held by MedtechLedger for P130021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130021

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalJan 17, 2014FDA
Medtronic, Inc.PMA supplementAug 14, 2025FDA
Medtronic, Inc.PMA supplementOct 22, 2025FDA
Medtronic, Inc.PMA supplementFeb 4, 2026FDA
Medtronic, Inc.PMA supplementFeb 10, 2026FDA
Medtronic, Inc.PMA supplementFeb 11, 2026FDA
Medtronic, Inc.PMA supplementFeb 12, 2026FDA
Medtronic, Inc.PMA supplementFeb 26, 2026FDA
Medtronic, Inc.PMA supplementMar 27, 2026FDA
Medtronic, Inc.PMA supplementJun 1, 2026FDA
Medtronic, Inc.PMA supplementJul 14, 2026FDA
Medtronic, Inc.PMA supplementAug 10, 2026FDA
Medtronic, Inc.PMA supplementNov 7, 2026FDA

Explore the linked device profile

Other records with product code NPT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
710 Medtronic Pkwy., Miinneapolis, MN, 55432

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records